Myokardia Inc (MYOK) Rises A lot Today, Is Now One of The Best Performer

September 17, 2017 - By Winifred Garcia

The stock of Myokardia Inc (NASDAQ:MYOK) is a huge mover today! The stock increased 4.65% or $2.05 on September 15, reaching $46.15. About 1.30M shares traded or 21.50% up from the average. Myokardia Inc (NASDAQ:MYOK) has risen 11.16% since September 17, 2016 and is uptrending. It has underperformed by 5.54% the S&P500.
The move comes after 7 months positive chart setup for the $1.61 billion company. It was reported on Sep, 17 by We have $47.53 PT which if reached, will make NASDAQ:MYOK worth $48.30M more.

Wall Street await Myokardia Inc (NASDAQ:MYOK) to release earnings on November, 6. Analysts forecast EPS of $-0.41, down exactly $0.06 or 17.14 % from 2014’s $-0.35 EPS. After posting $-0.41 EPS for the previous quarter, Myokardia Inc’s analysts now forecast 0.00 % EPS growth.

Myokardia Inc (NASDAQ:MYOK) Ratings Coverage

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. On Wednesday, July 20 the stock rating was initiated by BMO Capital Markets with “Outperform”. On Monday, November 23 the stock rating was initiated by Wedbush with “Outperform”. Cowen & Co initiated the shares of MYOK in report on Monday, November 23 with “Outperform” rating. The rating was initiated by Wells Fargo on Friday, December 4 with “Outperform”. The rating was initiated by Credit Suisse on Monday, November 23 with “Outperform”.

More recent Myokardia Inc (NASDAQ:MYOK) news were published by: which released: “MyoKardia to Present at Two Upcoming Investor Conferences in September” on August 30, 2017. Also published the news titled: “MyoKardia Appoints David Meeker, MD, to Board of Directors” on April 18, 2017.‘s news article titled: “MyoKardia hits life high after encouraging heart drug data” with publication date: August 07, 2017 was also an interesting one.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.61 billion. The Firm focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It currently has negative earnings. The Firm is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.